ahhhh master CPG
you forgot to add this bit
quote:
Advisory panel recommendations, however, are not binding on the FDA's decisions to approve or deny a drug. In a case opposite to what happened with Dendreon (Nasdaq: DNDN) earlier in the year, the FDA ignored the negative advisory panel vote about Relenza, eventually approving the drug anyway
end quote:
cheers
